The objective of current investigation is to study the relation between hyperglycosylated human chorionic gonadotropin and placenta accreta in the 3rd trimester of pregnancy. Patients and methods: The study included 44 patients indicated for elective caesarean section due to a sonographic diagnosis of placenta previa or placenta previa accreta. Ten ml of maternal blood was taken before delivery and serum was separated. Slices of placental tissue were taken and washed of blood. Sera and tissues were immediately stored in -80oC. Hyperglycosylated human chorionic gonadotrophin (hCG-H) assay was done by enzyme-linked immunosorbent assay for stored sera and homogenates of placental tissue. Placenta or hysterectomy specimens were sent for histopathological evaluation. Results: According to histopathological final diagnosis, patients were classified into 2 groups; placenta accreta spectrum group (study group, n=16) and placenta previa non-accreta spectrum group (control group n=28). Serum hCG-H level was statistically significant higher in placenta accreta group (1.35 ± 0.35 mIU/ml) as compared to placenta previa non accreta group (1.07 ± 0.3 mIU/ml) (p=0.02). Placental tissue hCG-H level was higher in accreta group (1.28±0.24) as compared to non accreta group (1.16±0.33 mIU/gram), but the difference was statistically insignificant (p=0.150). Conclusion: hCG-H may be a potential biomarker for predicting placenta accreta spectrum. More large-scale studies are needed to define the possibility of the presence of a reliable cut off diagnostic point. Combined with other possible biomarkers they can add to the diagnostic accuracy of already used imaging techniques